These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. D'Onofrio A; Gandolfi A Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598 [TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development. Phung MW; Dass CR J Pharm Pharmacol; 2006 Feb; 58(2):153-60. PubMed ID: 16451742 [TBL] [Abstract][Full Text] [Related]
4. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Nicoli S; Ribatti D; Cotelli F; Presta M Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396 [TBL] [Abstract][Full Text] [Related]
5. Selective targeting of the tumour vasculature. Chan LS; Daruwalla J; Christophi C ANZ J Surg; 2008 Nov; 78(11):955-67. PubMed ID: 18959693 [TBL] [Abstract][Full Text] [Related]
7. The angiogenic process as a therapeutic target in cancer. Bridges EM; Harris AL Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350 [TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Shojaei F; Ferrara N Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057 [TBL] [Abstract][Full Text] [Related]
11. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Dutour A; Rigaud M Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166 [TBL] [Abstract][Full Text] [Related]
12. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy]. Li H; Dkhissi F; Grenet C; Soria C; Lu H Therapie; 2001; 56(5):501-10. PubMed ID: 11806286 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of the tumor vasculature. Tozer GM; Bicknell R Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865 [TBL] [Abstract][Full Text] [Related]
15. Design and development of polymer conjugates as anti-angiogenic agents. Segal E; Satchi-Fainaro R Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Horsman MR; Siemann DW Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843 [TBL] [Abstract][Full Text] [Related]
18. Mitochondria as targets in angiogenesis inhibition. Park D; Dilda PJ Mol Aspects Med; 2010 Feb; 31(1):113-31. PubMed ID: 19995570 [TBL] [Abstract][Full Text] [Related]
19. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). d'Onofrio A; Gandolfi A Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652 [TBL] [Abstract][Full Text] [Related]
20. Cancer angiogenesis: targeting the heel of Achilles. Dass CR; Choong PF J Drug Target; 2008 Jul; 16(6):449-54. PubMed ID: 18604657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]